Revvity (RVTY) FDA Approvals $112.43 -0.52 (-0.46%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$112.32 -0.11 (-0.10%) As of 07/10/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Revvity's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Revvity (RVTY). Over the past two years, Revvity has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as T1D. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. T1D 4-plex FDA Regulatory Events T1D 4-plex is a drug developed by Revvity for the following indication: diabetic ketoacidosis (DKA). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 2,2025Provided Update Drug: T1D 4-plexAnnounced Date: October 2, 2025Indication: diabetic ketoacidosis (DKA)Other Companies Involved: NASDAQ:SNY AnnouncementRevvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.AI SummaryRevvity, Inc. and Sanofi have launched a program to expand testing for type 1 diabetes (T1D) by creating a new population‐scale assay for early detection. Building on Revvity’s research‐use 3-plex assay, the companies will develop a T1D 4-plex in vitro diagnostic (IVD) test. This assay will run on Revvity’s high‐throughput GSP® instrument and use both capillary dried blood spots and standard blood draws. By spotting autoimmune markers earlier, doctors can intervene sooner to slow disease progression and reduce the risk of serious complications like diabetic ketoacidosis. The collaboration will support clinical validation and regulatory filings, including submissions to the U.S. FDA and European IVDR authorities. In parallel, Revvity Omics will expand its existing lab-developed T1D test beyond its Pittsburgh facility, making the assay available at multiple global labs for broader patient access.Read Announcement Revvity FDA Events - Frequently Asked Questions Has Revvity received FDA approval? As of now, Revvity (RVTY) has not received any FDA approvals for its therapy in the last two years. What drugs has Revvity submitted to the FDA? In the past two years, Revvity (RVTY) has reported FDA regulatory activity for T1D 4-plex. What is the most recent FDA event for Revvity? The most recent FDA-related event for Revvity occurred on October 2, 2025, involving T1D 4-plex. The update was categorized as "Provided Update," with the company reporting: "Revvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay." What conditions do Revvity's current drugs treat? Currently, Revvity has one therapy (T1D 4-plex) targeting the following condition: diabetic ketoacidosis (DKA). More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events MIRA Pharmaceuticals FDA EventsDelcath Systems FDA EventsFate Therapeutics FDA EventsForte Biosciences FDA EventsGreenwich LifeSciences FDA EventsIN8bio FDA EventsINmune Bio FDA EventsIonis Pharmaceuticals FDA EventsCentury Therapeutics FDA EventsOpus Genetics FDA EventsMetaVia FDA EventsNeoGenomics FDA EventsQuoin Pharmaceuticals FDA EventsEli Lilly and Company FDA EventsArcutis Biotherapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Agilent Technologies FDA Events Eyepoint Pharmaceuticals FDA Events Quanterix FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NYSE:RVTY last updated on 10/2/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredJeff Brown and Marc Chaikin's latest AI prediction explainedJeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...Brownstone Research | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredSomething Bigger Than SpaceX is ComingLog Into Keith’s $5,000 “Forecast Calendar” An online calendar that shows you when the biggest stock jumps ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revvity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revvity With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 2,2025Provided Update Drug: T1D 4-plexAnnounced Date: October 2, 2025Indication: diabetic ketoacidosis (DKA)Other Companies Involved: NASDAQ:SNY AnnouncementRevvity, Inc. announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.AI SummaryRevvity, Inc. and Sanofi have launched a program to expand testing for type 1 diabetes (T1D) by creating a new population‐scale assay for early detection. Building on Revvity’s research‐use 3-plex assay, the companies will develop a T1D 4-plex in vitro diagnostic (IVD) test. This assay will run on Revvity’s high‐throughput GSP® instrument and use both capillary dried blood spots and standard blood draws. By spotting autoimmune markers earlier, doctors can intervene sooner to slow disease progression and reduce the risk of serious complications like diabetic ketoacidosis. The collaboration will support clinical validation and regulatory filings, including submissions to the U.S. FDA and European IVDR authorities. In parallel, Revvity Omics will expand its existing lab-developed T1D test beyond its Pittsburgh facility, making the assay available at multiple global labs for broader patient access.Read Announcement
